Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
- PMID: 17950857
- DOI: 10.1016/S0140-6736(07)61600-6
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
Abstract
Background: Increases in T helper (Th) 2 cytokine concentrations have been seen in atopic asthma, with interleukin 4 and interleukin 13 thought to have a role in the physiological response to allergen challenge. Our aim was to assess the therapeutic effect of pitrakinra, an interleukin-4 variant that targets allergic Th2 inflammation by potently inhibiting the binding of interleukin 4 and interleukin 13 to interleukin-4Ralpha receptor complexes.
Methods: In two independent randomised, double-blind, placebo-controlled, parallel group phase 2a clinical trials, patients with atopic asthma were treated with pitrakinra or placebo via two routes. In study 1, patients were randomly assigned to receive either 25 mg pitrakinra (n=12) or placebo (n=12) by subcutaneous injection once daily. In study 2, patients were randomly assigned to receive either 60 mg pitrakinra (n=16) or placebo (n=16) by nebulisation twice daily. Inhaled allergen challenge was done before and after 4 weeks of treatment. The primary endpoint for study 1 was maximum percentage decrease in forced expiratory volume in 1 s (FEV1) over 4-10 h after allergen challenge, whereas that in study 2 was average percentage decrease in FEV(1) over 4-10 h after allergen challenge. All patients except those with baseline data only were included in our analyses. These trials are registered with ClinicalTrials.gov, numbers NCT00535028 and NCT00535031.
Findings: No patients dropped out or were lost to follow-up in study 1; in study 2, two patients in the placebo group and one in the pitrakinra group dropped out or were lost to follow-up. These individuals had baseline data only, and were excluded from the analyses. In study 1, there was a 17.1% maximum percentage decrease in FEV1 in the pitrakinra group; by contrast, the maximum decrease was 23.1% in the placebo group (difference 6%, 95% CI -4.37 to 16.32; p=0.243). In study 2, there was a 4.4% average percentage decrease in FEV1 in the pitrakinra group; by contrast, the average percentage decrease was 15.9% in the placebo group (3.7 [95% CI 2.08-6.25] times lower in the pitrakinra group; p=0.0001). There were fewer asthma-related adverse events (p=0.069) and fewer adverse events requiring beta-agonist rescue (p=0.031) after subcutaneous administration of pitrakinra than with placebo. There were too few asthma-related adverse events in study 2 to assess the effect of inhalation of pitrakinra on adverse events.
Interpretation: Local treatment, targeted at inhibition of interleukins 4 and 13 in the lung, could substantially diminish the symptoms of asthma.
Comment in
-
Th2 cytokines in the asthma late-phase response.Lancet. 2007 Oct 20;370(9596):1396-8. doi: 10.1016/S0140-6736(07)61587-6. Lancet. 2007. PMID: 17950849 No abstract available.
Similar articles
-
Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial.Pulm Pharmacol Ther. 2006;19(4):233-41. doi: 10.1016/j.pupt.2005.07.004. Epub 2005 Sep 1. Pulm Pharmacol Ther. 2006. PMID: 16140027 Clinical Trial.
-
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.N Engl J Med. 2015 May 21;372(21):1987-95. doi: 10.1056/NEJMoa1411776. Epub 2015 May 17. N Engl J Med. 2015. PMID: 25981191 Clinical Trial.
-
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med. 2013 Nov;1(9):714-27. doi: 10.1016/S2213-2600(13)70187-5. Epub 2013 Oct 25. Lancet Respir Med. 2013. PMID: 24429275 Clinical Trial.
-
Targeting the interleukin pathway in the treatment of asthma.Lancet. 2015 Sep 12;386(9998):1086-96. doi: 10.1016/S0140-6736(15)00157-9. Lancet. 2015. PMID: 26383000 Review.
-
The pharmacological modulation of allergen-induced asthma.Inflammopharmacology. 2013 Apr;21(2):113-24. doi: 10.1007/s10787-012-0155-3. Epub 2012 Oct 25. Inflammopharmacology. 2013. PMID: 23096484 Review.
Cited by
-
Newer treatments in the management of pediatric asthma.Paediatr Drugs. 2013 Aug;15(4):291-302. doi: 10.1007/s40272-013-0020-x. Paediatr Drugs. 2013. PMID: 23754138 Review.
-
Using Periostin as a Biomarker in the Treatment of Asthma.Allergy Asthma Immunol Res. 2016 Nov;8(6):491-8. doi: 10.4168/aair.2016.8.6.491. Allergy Asthma Immunol Res. 2016. PMID: 27582399 Free PMC article. Review.
-
The Regulatory Effects of Interleukin-4 Receptor Signaling on Neutrophils in Type 2 Immune Responses.Front Immunol. 2019 Oct 24;10:2507. doi: 10.3389/fimmu.2019.02507. eCollection 2019. Front Immunol. 2019. PMID: 31708926 Free PMC article. Review.
-
Macmoondongtang modulates Th1-/Th2-related cytokines and alleviates asthma in a murine model.PLoS One. 2019 Dec 2;14(12):e0224517. doi: 10.1371/journal.pone.0224517. eCollection 2019. PLoS One. 2019. PMID: 31790411 Free PMC article.
-
The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.Arch Dermatol Res. 2020 Mar;312(2):81-92. doi: 10.1007/s00403-019-01972-3. Epub 2019 Sep 6. Arch Dermatol Res. 2020. PMID: 31493000 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical